Get started
Author

İsmail Bayrakçı

Observed names: BAYRAKÇI, İSMAİL, Bayrakci, Ismail, Bayrakçı, İsmail, Ismail Bayrakci, Ismail Bayrakcı, İsmail BAYRAKÇI, İsmail Bayrakci, İsmail Bayrakçi
ORCID: 0000-0002-5785-8273
Observed ORCID: 0000-0002-5785-8273
OpenAlex ID: A5017802314
The Effectiveness of Adjuvant PD-1 Inhibitors in Patients With Surgically Resected Stage III/IV Acral Melanoma
2024 · Haci Arak, Suna Erkiliç, et al. · Journal of Immunotherapy · 9
Prognostic value of the HALP score in metastatic castration-resistant prostate cancer: an analysis combined with time to castration resistance
2024 · İvo Gökmen, Nazan Demir, et al. · Frontiers in Oncology · 6
PDF
Evaluation of upper gastrointestinal system in acromegaly
2019 · Pinar Sisman, Murat Pekgoz, et al. · Annales d Endocrinologie · 6
The analysis of patients with primary and secondary glomerular diseases: A single-center experience
2016 · Yavuz Ayar, Alparslan Ersoy, et al. · Hong Kong Journal of Nephrology · 6
PDF
Gustave Roussy immune score as an independent prognostic factor for treatment response and survival in advanced renal cell carcinoma treated with nivolumab in second-line and beyond
2025 · Bülent Erdoğan, İvo Gökmen, et al. · Frontiers in Oncology · 5
PDF
Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis
2026 · Baris Koksal, Hasan Cagri Yildirim, et al. · Journal of Clinical Medicine · 2
PDF
Integration of Ki67 and Pan-Immune-Inflammation Value (PIV) into a predictive nomogram for pathologic complete response in triple-negative breast cancer
2026 · Taliha Guclu-Kantar, Ozgur Tanriverdi, et al. · BMC Cancer · 1
Prognostic Role of the Naples Score in Extensive-Stage Small Cell Lung Cancer: A Missed Opportunity in Inflammation-Based Stratification
2025 · Fahri Akgül, Ivo Gökmen, et al. · Journal of Clinical Medicine · 1
PDF
Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)
2025 · Nargiz Majidova, Sendag Yaslıkaya, et al. · The Turkish Journal of Gastroenterology · 1
PDF
Prognostic Significance of HALP Score in Second-Line Nivolumab Treatment of Advanced Non-Small Cell Lung Cancer
2025 · Fahri AKGÜL, İvo GÖKMEN, et al. · Namık Kemal Tıp Dergisi · 1
Adult Spermatic Cord Inflammatory Myofibroblastic Tumor: A Case-Based Narrative Review of The Literature
2026 · Bayrakçı, İsmail, Gökmen, İvo, et al. · Urology journal./Urology jornal.
PDF
Resection and pathological response after neoadjuvant nivolumab plus chemotherapy for lung cancer in a Turkish Oncology Group (TOG) real-world study
2026 · Erdem Sünger, Bahadır Köylü, et al. · Research Square
PDF
Divergent Prognostic Impact of Germline BRCA1 and BRCA2 Variants in Non-Metastatic Breast Cancer: A Real-World Cohort Study
2026 · Ismail Bayrakci, Rusen Cosar, et al. · Cancers
Prognostic Value of the Lung Immune Prognostic Index and an ECOG–Albumin–LIPI Nomogram in Metastatic NSCLC Patients Treated with Second- or Third-Line Nivolumab
2026 · Didem Divriklioğlu, İsmail Bayrakçı, et al. · Journal of Clinical Medicine
The CALLY Index Is Associated with Overall Survival in Patients with De Novo Metastatic Gastric Adenocarcinoma
2026 · Fahri Akgül, Süleyman Can, et al. · Medicina
Longer Diagnostic Delay and Post-Diagnosis Overall Survival in a Classic-Kaposi-Sarcoma-Predominant Retrospective Cohort
2026 · İsmail Bayrakçı, Didem Divriklioğlu, et al. · Journal of Clinical Medicine
Temporal Trends in Clinicopathological Features and Outcomes of De Novo Metastatic Luminal A Breast Cancer: A Retrospective Multicenter Analysis (2017–2025)
2026 · Bilgin Demir, Özgür Tanrıverdi, et al. · Cancer Investigation
Proliferation-Guided Risk Stratification in HER2-Low versus HER2-Positive Hormone Receptor-Positive Breast Cancer: A Multicenter Retrospective Analysis
2026 · Sait Kitapli, Özgür Tanrıverdi, et al. · Oncology Research and Treatment
Temporal Trends in Clinicopathological Features and Outcomes of De Novo Metastatic Luminal A Breast Cancer: A Retrospective Multicenter Analysis (2017–2025)
2026 · Demir, Bilgin, Tanrıverdi, Özgür, et al. · Figshare
Aggressive Paratesticular Spindle Cell Rhabdomyosarcoma in an Adult: A Rare Case and Review of Reported Adult Cases
2025 · İsmail Bayrakçı, İvo Gökmen, et al. · Clinical Genitourinary Cancer
PDF
Efficacy of Subsequent Therapy in Patients with Hormone-Positive Advanced Breast Cancer with Disease Progression After CDK4/6 Inhibitor Therapy: Multicenter Real-Life Data
2025 · Buket Şahin Çelik, Aslı Geçgel, et al. · Journal of Clinical Medicine
PDF
Extra-gastrointestinal stromal tumor of the prostate — a case report and literature review
2025 · Tayyip İlker Aydın, Gökhan Öztürk, et al. · Oncology in Clinical Practice
PDF
Antibody-Drug Conjugates as a Potential a Systemic Treatment Strategy for Brain Metastases in Cases of Solid Tumors
2025 · Didem DİVRİKLİOĞLU, İsmail BAYRAKÇI, et al. · Journal of Oncological Sciences
PDF
Niraparib-Associated Pulmonary Embolism in a Patient with BRCA Mutant Ovarian Cancer
2025 · Aysun Fatma AKKUŞ, Gökhan ÖZTÜRK, et al. · Turkiye Klinikleri Journal of Case Reports
PDF
Prognostic Factors in Brain Metastatic Breast Cancer Patients and Comparison of Breast Graded Prognostic Assessment Scores
2024 · İvo Gökmen, Nazan Demir, et al. · SSRN Electronic Journal
Works count: 34
Citation count: 38
H-index: 5
I10-index:
Year
Topic
Type